Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Nigella Sativa  COVID-19 treatment studies for Nigella Sativa  C19 studies: Nigella Sativa  Nigella Sativa   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Nigella Sativa for COVID-19: real-time meta analysis of 10 studies
Covid Analysis, September 29, 2022, DRAFT
https://c19ns.com/meta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 82% 0.18 [0.04-0.80] death 2/157 11/156 CT​1 Improvement, RR [CI] Treatment Control Ashraf (RCT) 67% 0.33 [0.01-7.99] death 0/107 1/103 CT​1 Ashraf (RCT) 79% 0.21 [0.05-0.92] death 2/50 10/53 CT​1 Ashraf (RCT) 84% 0.16 [0.11-0.24] no recov. 107 (n) 103 (n) CT​1 Ashraf (RCT) 75% 0.25 [0.15-0.41] no recov. 50 (n) 53 (n) CT​1 Ashraf (RCT) 82% 0.18 [0.12-0.27] viral+ 107 (n) 103 (n) CT​1 Ashraf (RCT) 77% 0.23 [0.14-0.38] viral+ 50 (n) 53 (n) CT​1 Al-Haidari (RCT) 96% 0.04 [0.00-0.70] death 0/160 14/259 Al-Haidari (RCT) 93% 0.07 [0.02-0.30] severe case 2/160 44/259 Aldwihi 24% 0.76 [0.54-1.03] hosp. 85/345 152/393 Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Koshak (RCT) 43% 0.57 [0.42-0.78] no recov. 34/91 60/92 Bencheqr.. (DB RCT) 69% 0.31 [0.01-7.19] hosp. 0/29 1/23 Bencheqr.. (DB RCT) 9% 0.91 [0.48-1.72] no improv. 28 (n) 23 (n) Bencheqr.. (DB RCT) 35% 0.65 [0.29-1.43] no improv. 28 (n) 23 (n) Bencheqr.. (DB RCT) 43% 0.57 [0.22-1.43] viral+ 5/21 8/19 Karimi (RCT) 51% 0.49 [0.09-2.66] death 2/192 4/189 CT​1 Karimi (RCT) 61% 0.39 [0.08-2.00] ICU 2/192 5/189 CT​1 Karimi (RCT) 70% 0.30 [0.15-0.61] hosp. 184 (n) 174 (n) CT​1 Karimi (RCT) 67% 0.33 [0.17-0.65] no recov. 184 (n) 174 (n) CT​1 Karimi (RCT) 14% 0.86 [0.80-0.93] no recov. 184 (n) 174 (n) CT​1 Setayesh (RCT) -8% 1.08 [0.07-16.7] death 1/38 1/41 CT​1 Setayesh (RCT) 27% 0.73 [0.58-0.92] oxygen time 38 (n) 41 (n) CT​1 Setayesh (RCT) 29% 0.71 [0.63-0.81] hosp. time 38 (n) 41 (n) CT​1 Al-Haidari 62% 0.38 [0.31-0.46] symp. case 68/188 180/188 Shehab 0% 1.00 [0.36-2.74] severe case 4/39 22/214 Chandra (RCT) 49% 0.51 [0.16-1.59] cases 4/52 8/53 CT​1 Chandra (RCT) 87% 0.13 [0.02-1.00] cases 1/51 8/53 CT​1 Chandra (RCT) 74% 0.26 [0.06-1.17] cases 2/51 8/53 CT​1 nigella sativa COVID-19 outcomes c19ns.com Sep 2022 1 CT: study uses combined treatment Favors nigella sativa Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit